

CPT[®] Category I Pathology and Laboratory and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

Most recent changes to this medium descriptor document:

• Addition of 2 Category I codes (86413, 99072) accepted by the CPT Editorial Panel.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

Code	Medium Code Descriptor	Released to AMA website	Effective	Publicatior
●87635	IADNA SARS-COV-2 COVID-19 AMPLIFIED PROBE TQ March 13, 2020		March 13, 2020	CPT [®] 2021
	g codes were accepted and revised at the April 2020 CPT Edito codes are effective immediately on April 10, 2020.	orial Panel meeting	for the 2021 CPT p	roduction
▲86318	IMMUNOASSAY INFECTIOUS AGT ANTIBODY QUAL/SEMIQUAN 1-STEP METH April 10, 2020		April 10, 2020	CPT [®] 2021
#●86328	IA INFECTIOUS AGT ANTIBODY SARS-COV-2 COVID-19 April 10, 2020		April 10, 2020	CPT [®] 2021
●86769	ANTB SEVERE AQT RESPIR SYND SARS-COV-2 COVID-	April 10, 2020	April 10, 2020	CPT [®] 2021



CPT[®] Category I Pathology and Laboratory and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

●87426	IAAD	IA SEVERE AG	T RESPIR SYND CORONAVIRUS	June	25, 2020	June 25, 20)20	CPT [®] 2022	
The following	The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on August 10, 2020.								
#●86408	NEUTRALIZING ANTIBODY SARS-COV-2 SCREEN			Augus	t 10, 2020	August 10, 2	2020	CPT [®] 2022	
#●86409	NEUTRALIZING ANTIBODY SARS-COV-2 TITER			Augus	t 10, 2020	August 10, 2	2020	CPT [®] 2022	
The following	The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on September 8, 2020.								
#●86413	SEV AQT RESPIR SYND CORONAVIRUS 2 ANTIBODY QUAN		September 8, 2020		September 2020	[.] 8,	CPT [®] 2022		
●99072	ADDL SUPL MATRL&STAF TM DRG PHE RES-TR NFCT DS			September 8, Se 2020		September 2020	⁻ 8,	CPT [®] 2022	
The following code was accepted by the Executive Committee of the CPT Editorial Panel for the 2021 CPT production cycle. This code is effective immediately on May 20, 2020.								ction cycle.	
Proprietary and Clin Laborator Manufact	ical ry or	Code	Medium Code Descriptor		Released AMA Website	Effectiv	/e	Publication	



CPT[®] Category I Pathology and Laboratory and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

BioFire [®] Respiratory Panel 2.1 (RP2.1), BioFire [®] Diagnostics, BioFire [®] Diagnostics, LLC	₩ ●0202U	NFCT DS BCT/VIR RESPIR DNA/RNA 22 TRGT SARSCOV2	May 20, 2020	May 20, 2020	CPT [®] 2021 Duplicate PLA Symbol Added to Publication CPT [®] 2022			
The following codes were accepted by the Executive Committee of the CPT Editorial Panel. These codes are effective immediately on June 25, 2020.								
QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH	₩ ●0223U	NFCT DS BCT/VIR RESPIR DNA/RNA 22 TRGT SARSCOV2	June 25, 2020	June 25, 2020	CPT [®] 2022			
COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory	●0224U	ANTB SEV AQT RESPIR SYND CORONAVIRUS 2 TITER(S)	June 25, 2020	June 25, 2020	CPT [®] 2022			
The following codes v	vere accepted	by the CPT Editorial Panel. These codes are eff	ective immedia	tely on Augu	st 10, 2020.			
ePlex [®] Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc	●0225U	NFCT DS DNA&RNA 21 TARGETS SARS- COV-2 AMP PROBE	August 10, 2020	August 10, 2020	CPT [®] 2022			
Tru-Immune TM , Ethos Laboratories, GenScript [®] USA Inc	●0226U	SUROGAT VIR NEUTRLZJ TST SARSCOV2 ELISA PLSM SRM	August 10, 2020	August 10, 2020	CPT [®] 2022			